公开(公告)号：EP1831170A1

公开(公告)日：2007-09-12

申请号：EP05815781.9

申请日：2005-12-12

申请人： AstraZeneca AB ,  Astex Therapeutics Limited

发明人： ALBERT, Jeffrey Scott AstraZeneca Wilmington ,  CALLAGHAN, Owen ,  CAMPBELL, James AstraZeneca Wilmington ,  CARR, Robin, Arthur, Ellis ,  CHESSARI, Gianni Astex Therapeutics ,  COWAN, Suzanna ,  CONGREVE, Miles Stuart Astex Therapeutics ,  EDWARDS, Phil AstraZeneca Wilmington ,  FREDERICKSON, Martyn Astex Therapeutics ,  MURRAY, Christopher William Astex Therapeutics ,  PATEL, Sahil Astex Therapeutics

IPC分类号： C07D213/73 ,  A61K31/44 ,  A61P25/16 ,  A61P25/28

CPC分类号： C07D213/73 ,  C07D213/74 ,  C07D213/81 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/10 ,  C07D409/14 ,  C07D413/12

摘要： This invention relates to novel compounds having the structural formula (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.